• Trametinib (GSK1120212) Experimental Workflows

  2026-09-14

  Build reproducible MEK-ERK pathway experiments with Trametinib (GSK1120212), from DMSO stock preparation through phospho-ERK and viability readouts. The workflow emphasizes hypoxia-associated EGFR inhibitor resistance, B-RAF model selection, combination design, and practical troubleshooting.

• Neuroligin 1 Proteolysis Sustains Social Memory

  2026-09-14

  Liu and colleagues identify social interaction-induced cleavage of Neuroligin 1 in the ventral hippocampus as a mechanism that maintains, rather than merely forms, social memory. Their results connect secretase processing, the NLG1-CTD PDZ-binding domain, cofilin signaling, and dendritic spine remodeling, suggesting experimentally testable routes for studying short-term memory persistence.

• Partial BACE1 Inhibition and Synaptic Transmission

  2026-09-13

  Satir et al. used optical electrophysiology and amyloid-beta measurements in primary rat cortical neurons to test whether moderate β-secretase inhibition can lower Aβ secretion without disrupting neuronal communication. The study found that Aβ production could be reduced by up to approximately 50% without measurable synaptic impairment, whereas stronger inhibition reduced synaptic transmission, defining an exposure-dependent safety window for Alzheimer’s disease research.

• Fluo-4 AM: Mechanism, Workflow, and Limits

  2026-09-12

  Fluo-4 AM is a cell-permeant fluorescent calcium indicator for monitoring intracellular Ca2+ dynamics. Its acetoxymethyl ester chemistry supports membrane loading, while intracellular hydrolysis releases a dye whose fluorescence increases after Ca2+ binding.

• Rocilinostat (ACY-1215) Research Workflows

  2026-09-11

  Build reproducible HDAC6-engagement, multiple myeloma viability, and proteasome-inhibitor combination assays with Rocilinostat (ACY-1215). This guide also shows how to extend the compound into exploratory cilia research without confusing HDAC6 pharmacology with the SMPD4–ceramide mechanism.

• NF 340: P2Y11 Antagonist Evidence

  2026-09-11

  NF 340 (SKU B7508) is a selective P2Y11 antagonist for studying purinergic GPCR signaling. Peer-reviewed breast cancer data associate NF 340 treatment with reduced QPRT-associated invasion and myosin light-chain phosphorylation, while product specifications define its formulation and handling requirements.

• Bifendate Attenuates Hepatic Steatosis in Mice

  2026-09-10

  The 2006 European Journal of Pharmacology study showed that Bifendate, or DDB, consistently reduced hepatic cholesterol and triglyceride accumulation across several mouse models of diet- and cholesterol-induced hypercholesterolemia. Its key contribution was to distinguish liver lipid reduction from systemic lipid lowering, providing a useful framework for studying hepatoprotection and hepatic lipid metabolism rather than treating DDB as a conventional serum lipid-lowering drug.

• FH1 Small Molecule for iHep Maturation

  2026-09-10

  FH1 (Catalog No. B3700) supports a more functional hepatocyte-like cell workflow by pairing morphology with albumin, CYP3A4, and AFP readouts. This guide shows how to build a controlled iPS differentiation experiment, troubleshoot inconsistent maturation, and evaluate how improved cell state may support regulated gene-expression studies.

• Arrb2–6-ketoLCA Signaling in Hepatic IRI

  2026-09-09

  The reference study identifies hepatocyte β-arrestin 2 (Arrb2) as a protective regulator of hepatic ischemia–reperfusion injury, linking parenchymal signaling to increased 6-ketoLCA and M2 macrophage polarization. Its combination of clinical association analysis, hepatocyte-focused mouse genetics, hypoxia–reoxygenation experiments, and metabolomics offers a useful framework for studying hepatocyte–macrophage communication in transplantation-related inflammation.

• Ferrostatin-1 in NRF2-Linked Ferroptosis Assays

  2026-09-09

  Ferrostatin-1 (Fer-1) is a selective tool for separating ferroptotic lipid damage from broader oxidative and inflammatory effects. This article explains how to use Fer-1 as a mechanistic rescue control in NRF2-focused alcoholic liver disease assays and related disease models.

• Saracatinib (AZD0530) Assay Workflows

  2026-09-08

  Build reproducible Src/Abl inhibition studies with Saracatinib (AZD0530), from dose-response and migration assays to pathway validation. The workflow also explains how findings on Reelin–SFK signaling can inform exploratory neurobiology without overstating cross-domain evidence.

• MK-5108 (VX-689): From Target to Tumor Model

  2026-09-08

  Explore how MK-5108 (VX-689), a highly selective Aurora A inhibitor, can connect target validation with cancer cell line proliferation assays and xenograft studies. This article emphasizes assay design, evidence interpretation, and translational limitations rather than repeating standard product or disease summaries.

• Caspase-3 Fluorometric Assay Kit Workflow

  2026-09-07

  Turn apoptosis experiments into quantitative caspase activity measurements with a fast DEVD-AFC fluorescence workflow. This guide shows how to connect treatment design, autophagy–apoptosis biology, controls, and troubleshooting for more interpretable results.

• ABT-888 (Veliparib) in Translational DDR Research

  2026-09-07

  ABT-888 (Veliparib) offers translational researchers a selective PARP1/2 perturbation tool for testing DNA repair inhibition, chemotherapy and radiation sensitization, and genotype-dependent response. This thought-leadership analysis connects preclinical colorectal cancer evidence with a recent acute leukemia study showing why DNA damage-response combinations must be evaluated in the correct biological context.

• c-Myc Tag Peptide: From Assay Control to Translation

  2026-09-05

  A mechanistic and strategic guide to using the c-Myc tag Peptide for epitope-specific assay control, fusion-protein displacement, and more disciplined translational studies of transcription factor regulation.

8493 records 1/567 page Next 12345 下5页 Last page